共 50 条
A Double-Layered Covered Biliary Metal Stent for the Management of Unresectable Malignant Biliary Obstruction: A Multicenter Feasibility Study
被引:3
|作者:
Park, Jin-Seok
[1
]
Jeong, Seok
[1
,2
]
Lee, Don Haeng
[1
,2
,3
]
Moon, Jong Ho
[4
,5
]
Lee, Kyu Taek
[6
]
Dong, Seok Ho
[7
]
机构:
[1] Inha Univ, Dept Internal Med, Ctr Digest Dis, Sch Med, Inchon, South Korea
[2] Natl Ctr Efficacy Evaluat Dev Hlth Prod Targeting, Inchon, South Korea
[3] Utah Inha DDS & Adv Therapeut Res Ctr, Inchon, South Korea
[4] Soonchunhyang Univ, Sch Med, Digest Dis Ctr, Bucheon, South Korea
[5] Soonchunhyang Univ, Sch Med, Res Inst, Dept Internal Med, Bucheon, South Korea
[6] Sungkyunkwan Univ, Div Gastroenterol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea
[7] Kyung Hee Univ, Div Gastroenterol & Hepatol, Dept Internal Med, Sch Med, 26 Kyungheedae Ro, Seoul 02447, South Korea
关键词:
Stents;
Extrahepatic cholestasis;
Feasibility studies;
Common bile duct neoplasms;
Adverse effects;
RANDOMIZED-TRIAL;
CHOLECYSTITIS;
STRICTURES;
WALLSTENT;
EFFICACY;
TEFLON;
D O I:
10.5009/gnl15112
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Background/Aims: The covered self-expandable metal stent (CMS) was developed to prevent tumor ingrowth-induced stent occlusion during the treatment of malignant biliary obstruction. However, complications such as cholecystitis, pancreatitis, and stent migration can occur after the endoscopic insertion of CMSs. The aim of the present study was to assess the efficacy and safety of a double-layered CMS (DCMS) for the management of malignant bile duct obstruction. Methods: DCMSs were endoscopically introduced into 59 patients with unresectable malignant extrahepatic biliary obstruction at four tertiary referral centers, and the patient medical records were retrospectively reviewed. Results: Both the technical and functional success rates were 100%. Procedure-related complications including pancreatitis, cholangitis, stent migration, and liver abscess occurred in five patients (8.5%). The median follow-up period was 265 days (range, 31 to 752 days). Cumulative stent patency rates were 68.2% and 40.8% at 6 and 12 months, respectively. At the final follow-up, the rate of stent occlusion was 33.9% (20/59), and the median stent patency period was 276 days (range, 2 to 706 days). Conclusions: The clinical outcomes of DCMSs were comparable to the outcomes previously reported for CMSs with respect to stent patency period and complication rates.
引用
收藏
页码:969 / 974
页数:6
相关论文